{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:49:18Z","timestamp":1791143358085,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s12094-012-0785-3","type":"journal-article","created":{"date-parts":[[2012,3,12]],"date-time":"2012-03-12T22:18:05Z","timestamp":1331590685000},"page":"207-213","source":"Crossref","is-referenced-by-count":21,"title":["Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients"],"prefix":"10.1007","volume":"14","author":[{"given":"Xiaoxia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikramsingh Kim","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"key":"785_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A. Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"785_CR2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/jjco\/hyq031","volume":"40","author":"E. Tahara","year":"2009","unstructured":"Tahara E, Yasui W, Ito H et al (2009) Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities\u2019 Consortium International Symposium. Jpn J Clin Oncol 40:702\u2013708","journal-title":"Jpn J Clin Oncol"},{"key":"785_CR3","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","volume":"27","author":"B.H. Gr\u00f8nberg","year":"2009","unstructured":"Gr\u00f8nberg BH, Bremnes RM, Fl\u00f8tten O et al (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-smallcell lung cancer. J Clin Oncol 27:3217\u20133224","journal-title":"J Clin Oncol"},{"key":"785_CR4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF03256260","volume":"11","author":"L. Gossage","year":"2007","unstructured":"Gossage L, Madhusudan S (2007) Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 11:361\u2013380","journal-title":"Mol Diagn Ther"},{"key":"785_CR5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/carcin\/22.9.1437","volume":"22","author":"G. Matullo","year":"2001","unstructured":"Matullo G, Palli D, Peluso M et al (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22:1437\u20131445","journal-title":"Carcinogenesis"},{"key":"785_CR6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/carcin\/23.2.295","volume":"23","author":"Y. Qiao","year":"2002","unstructured":"Qiao Y, Spitz MR, Shen H et al (2002) Modulation of repair of ultraviolet damage in the host cell reactivation assay by polymorphic XPC and XPD\/ERCC2 genotypes. Carcinogenesis 23:295\u2013299","journal-title":"Carcinogenesis"},{"key":"785_CR7","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/jjco\/hyq071","volume":"40","author":"C. Zhou","year":"2010","unstructured":"Zhou C, Ren S, Zhou S et al (2010) Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 40:954\u2013960","journal-title":"Jpn J Clin Oncol"},{"key":"785_CR8","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nature04226","volume":"437","author":"International HapMap Consortium","year":"2005","unstructured":"International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299\u20131320","journal-title":"Nature"},{"key":"785_CR9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ijc.1228","volume":"92","author":"G. Matullo","year":"2001","unstructured":"Matullo G, Guarrera S, Carturan S et al (2001) DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 92:562\u2013567","journal-title":"Int J Cancer"},{"key":"785_CR10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/annonc\/mdj135","volume":"17","author":"R. Pe\u00f1as de las","year":"2006","unstructured":"de las Pe\u00f1as R, Sanchez-Ronco M, Alberola V et al (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17:668\u2013675","journal-title":"Ann Oncol"},{"key":"785_CR11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/jnci\/94.14.1091","volume":"94","author":"C.H. Bosken","year":"2002","unstructured":"Bosken CH, Wei Q, Amos CI et al (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94:1091\u20131099","journal-title":"J Natl Cancer Inst"},{"key":"785_CR12","first-page":"1215","volume":"30","author":"Z. Zhang","year":"2007","unstructured":"Zhang Zl, Zhou CC, Zhang J et al (2007) Relationship between polymorphisms of DNA repair gene XRCC3 and susceptibility to lung cancer. Chin J Tuberculosis Resp Dis 30:1215\u20131220","journal-title":"Chin J Tuberculosis Resp Dis"},{"key":"785_CR13","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/carcin\/bgi345","volume":"27","author":"H. Sch\u00f6llnberger","year":"2006","unstructured":"Sch\u00f6llnberger H, Manuguerra M, Bijwaard H et al (2006) Analysis of epidemiological cohort data on smoking effects and lung cancer with a multistage cancer model. Carcinogenesis 27:1432\u20131444","journal-title":"Carcinogenesis"},{"key":"785_CR14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/carcin\/bgi232","volume":"27","author":"S. Zienolddiny","year":"2006","unstructured":"Zienolddiny S, Campa D, Lind H et al (2006) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27:560\u2013567","journal-title":"Carcinogenesis"},{"key":"785_CR15","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","volume":"15","author":"D. Isla","year":"2004","unstructured":"Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194\u2013203","journal-title":"Ann Oncol"},{"key":"785_CR16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2003.11.019","volume":"44","author":"J.S. Ryu","year":"2004","unstructured":"Ryu JS, Hong YC, Han HS et al (2004): Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44:311\u2013316","journal-title":"Lung Cancer"},{"key":"785_CR17","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.1200\/jco.2006.24.18_suppl.7055","volume":"24","author":"R. Rosell-Costa","year":"2006","unstructured":"Rosell-Costa R, Alberola V, Camps C et al (2006) Clinical outcome of gemcitabine (gem)\/cisplatin (cis)-vs docetaxel (doc)\/cis-treated stage IV non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age. J Clin Oncol 24:7055","journal-title":"J Clin Oncol"},{"key":"785_CR18","first-page":"205","volume":"92","author":"P. Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205\u2013216","journal-title":"European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst"},{"key":"785_CR19","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","volume":"22","author":"S. Gurubhagavatula","year":"2004","unstructured":"Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594\u20132601","journal-title":"J Clin Oncol"},{"key":"785_CR20","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1158\/1078-0432.CCR-04-0247","volume":"10","author":"W. Zhou","year":"2004","unstructured":"Zhou W, Gurubhagavatula S, Liu G et al (2004) Excision repair ross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939\u20134943","journal-title":"Clin Cancer Res"},{"key":"785_CR21","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/carcin\/23.8.1321","volume":"23","author":"S. Chen","year":"2002","unstructured":"Chen S, Tang D, Xue K et al (2002) DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 23:1321\u20131325","journal-title":"Carcinogenesis"},{"key":"785_CR22","first-page":"5457","volume":"62","author":"R. Aloyz","year":"2002","unstructured":"Aloyz R, Xu ZY, Bello V et al (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62:5457\u20135462","journal-title":"Cancer Res"},{"key":"785_CR23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2010.11.004","volume":"73","author":"L. Liu","year":"2010","unstructured":"Liu L, Yuan P, Wu C et al (2010) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73:110\u2013115","journal-title":"Lung Cancer"},{"key":"785_CR24","first-page":"859","volume":"10","author":"C.Y. Yao","year":"2009","unstructured":"Yao CY, Huang XE, Li C et al (2009) Lack of in-fluence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 10:859\u2013864","journal-title":"Asian Pac J Cancer Prev"},{"key":"785_CR25","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-07-1364","volume":"14","author":"C. Tibaldi","year":"2008","unstructured":"Tibaldi C, Giovannetti E, Vasile E et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797\u20131803","journal-title":"Clin Cancer Res"},{"key":"785_CR26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.bjc.6601975","volume":"91","author":"J. Stoehlmacher","year":"2004","unstructured":"Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU\/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344\u2013354","journal-title":"Br J Cancer"},{"key":"785_CR27","first-page":"8654","volume":"61","author":"D.J. Park","year":"2001","unstructured":"Park DJ, Stoehlmacher J, Zhang W et al (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654\u20138658","journal-title":"Cancer Res"},{"key":"785_CR28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.critrevonc.2005.01.005","volume":"54","author":"J. Robert","year":"2005","unstructured":"Robert J, Morvan VL, Smith D et al (2005) Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54:171\u2013196","journal-title":"Crit Rev Oncol Hematol"},{"key":"785_CR29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000086499","volume":"28","author":"J. Stohlmacher","year":"2005","unstructured":"Stohlmacher J (2005) Pharmacogenetics in gastrointestinal tumors. Onkologie 28:435\u2013440","journal-title":"Onkologie"},{"key":"785_CR30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ctrv.2004.12.006","volume":"31","author":"D.M. Kweekel","year":"2005","unstructured":"Kweekel DM, Gelderblom H, Guchelaar HJ (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90\u2013105","journal-title":"Cancer Treat Rev"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-012-0785-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-012-0785-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-012-0785-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T23:16:08Z","timestamp":1593818168000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-012-0785-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1007\/s12094-012-0785-3","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}